» Articles » PMID: 17322922

Targeted Therapy for Cancer Stem Cells: the Patched Pathway and ABC Transporters

Overview
Journal Oncogene
Date 2007 Feb 27
PMID 17322922
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

Data from certain leukemias as well as brain and breast cancer indicate that there is a small population of tumor cells with "stem cell" characteristics and the capacity for self-renewal. The self-renewing cells have many of the properties of normal stem cells and have been termed "cancer stem cells". These cancer stem cells make up as few as 1% of the cells in a tumor, making them difficult to detect and study. Like normal stem cells, cancer stem cells have a number of properties permitting them to survive traditional cancer chemotherapy and radiation therapy. These cells express high levels of ATP-binding cassette (ABC) drug transporters, providing for a level of resistance; are relatively quiescent; have higher levels of DNA repair and a lowered ability to enter apoptosis. Combined cancer therapy approaches targeting the cancer stem cells and the non-stem cells may be developed with increased efficacy. Efforts to target the Hedgehog/Patched pathway, critical to embryonic growth and differentiation, and the ABCG2 drug efflux transporter will be presented.

Citing Articles

Cancer stem cell populations are resistant to 5-aminolevulinic acid-photodynamic therapy (5-ALA-PDT).

Rice C, Chelakkot V, Conohan N, Hirasawa K Sci Rep. 2025; 15(1):4367.

PMID: 39910203 PMC: 11799205. DOI: 10.1038/s41598-025-88173-3.


Cholesterol neutralized vemurafenib treatment by promoting melanoma stem-like cells via its metabolite 27-hydroxycholesterol.

Wang X, Zhong F, Chen T, Wang H, Wang W, Jin H Cell Mol Life Sci. 2024; 81(1):226.

PMID: 38775844 PMC: 11111659. DOI: 10.1007/s00018-024-05267-3.


Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy.

Cao J, Zhang Z, Zhou L, Luo M, Li L, Li B MedComm (2020). 2023; 4(6):e427.

PMID: 38045829 PMC: 10693315. DOI: 10.1002/mco2.427.


Cancer Chemoresistance; Recent Challenges and Future Considerations.

Adil M, Kanwal S, Rasheed S, Iqbal M, Abbas G Cancer Treat Res. 2023; 185:237-253.

PMID: 37306912 DOI: 10.1007/978-3-031-27156-4_12.


Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma.

Jiang L, Li L, Liu Y, Lu L, Zhan M, Yuan S Front Pharmacol. 2023; 14:1097277.

PMID: 36891274 PMC: 9987615. DOI: 10.3389/fphar.2023.1097277.